Protalix
Recombinant Therapeutics Proteins Using Plant Cell-Based Expression System.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (39 %) | 24 % | 37 % | (18 %) | 8 % | 83 % | 52 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (52 %) | (25 %) | 20 % | 12 % | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (72 %) | (31 %) | 13 % | 5 % | 25 % | 46 % | 59 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 78 % | 62 % | 26 % | 24 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Protalix is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based protein expression system. The company focuses on creating potentially superior versions of existing therapeutic proteins, targeting established pharmaceutical markets. Protalix serves patients with respiratory diseases and rare conditions such as Fabry disease. Its business model revolves around advancing its pipeline through clinical trials and eventually bringing these therapies to market. Revenue is generated through the commercialization of these therapeutic proteins, either directly or through partnerships with other pharmaceutical companies.
Keywords: biopharmaceutical, recombinant proteins, ProCellEx, respiratory diseases, Fabry disease, clinical trials, plant cell-based, therapeutic proteins, commercialization, partnerships.